Draegerwerk Ag & Co. Kgaa · XETR:DRW8

Draegerwerk Ag & Co. Kgaa — Drägerwerk AG & Co. KGaA — Investor Presentation (March 2022)

35 slides from Draegerwerk Ag & Co. Kgaa's investor presentation, Mar 4, 2022

  1. Slide 1: Capital Markets Presentation Drägerwerk AG & Co. KGaA

    Capital Markets Presentation Drägerwerk AG & Co. KGaA March 2022, Lübeck Drägerwerk AGAG © Drägerwerk & Co. KGaA, & Co. 2022 KGaA, 2020

  2. Slide 2: Disclaimer

    Disclaimer This presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase any securities. No money, securities or other consideration is being solicited by this presentation. This presentation contains forward-looking statements regarding the future d

  3. Slide 3: Dräger, The Company, Financials, Outlook

    Dräger The Company Financials Outlook Drägerwerk AGAG & Co. KGaA, 2022 © Drägerwerk & Co. KGaA, 2020 3

  4. Slide 4: Dräger products protect, support and save lives

    Dräger products protect, lives support and save Drägerwerk AGAG & Co. KGaA, 2022 © Drägerwerk & Co. KGaA, 2020 4

  5. Slide 5: Net sales development

    Net sales development Strong growth independent of the global economy COVID-19 4000 pandemic 3500 Debt crisis 3000 Financial Stock- crisis 2500 market Russian 2000 Mexican financial crash peso crisis 1500 crisis 1000 500 0 1990 1992 1993 1994 1995 1996 1997 1998 2000 2002 2003 2004 2005 2006 2007 20

  6. Slide 6: Dräger worldwide

    Dräger worldwide Net sales, Employees and sites 18% ~32% Safety Division Net sales: EUR ~68% Medical Division 3.3 billion in 2021** 24% 58% 20% Production, Quality, 15% Logistics & Purchasing 59% Sales & Service 15% 15.657 15,900 10% Mitarbeiter Employees in R&D in 2021* 2020* 70% 11% Administration

  7. Slide 7: Markets

    Markets Our Customers Hospital Fire services Oil and gas industry Mining Chemical industry Other markets Drägerwerk AGAG & Co. KGaA, 2022 © Drägerwerk & Co. KGaA, 2020 7

  8. Slide 8: Medical Division

    Medical Division Hospital wide Intensive Care Operating Room Neonatal Care Solutions Anaesthesiology  Anaesthesia workstations Patient Monitoring & Clinical IT and vaporizers  #1 in Europe and   #2 in the US market  Infinity Acute Care System  Clincal software solutions  Telemetry and IT-solu

  9. Slide 9: Safety Division

    Safety Division Fire Service Oil & Gas Chemical Mining Other Markets Breathing Systems  Self-contained Breathing Impairment Check Equipment Appartus for fire fighters  #2 worldwide and       Alcohol- and drug screening #1 in Europe devices  Interlock devices Gas Detection Systems   #1 wor

  10. Slide 10: Medical and safety technology providing long-term growth prospects

    Medical and safety technology providing long-term growth prospects Medical division Safety division Attractive growth prospects  Average expected annual market growth for the  Very diversified markets with numerous product and in sizeable markets … global medical equipment market significantly ser

  11. Slide 11: Technology and innovation leadership to drive profitable growth

    Technology and innovation leadership to drive profitable growth Strong R&D focus Innovation to enhance future growth (examples)  Approximately ~1,500 employees in R&D around the globe.  EUR ~329 million spent for R&D activities in 2021.*  Certified test-center at Lübeck headquarter supports innov

  12. Slide 12: Exploit growth potentials in developing countries

    Exploit growth potentials in developing countries  Focus on the specific needs of customer in developing countries  Identify growth potential in strong growing markets like China, Brazil and India Investments in profitable  Capitalize on the significant investments into the Sales & Service infras

  13. Slide 13: Service- and consumables business a clear focus of our sales activities

    Service- and consumables business a clear focus of our sales activities Further expansion of  Capitalize on large installed base to expand after sales business service and consumables  Focus on combined sale of equipment and after sales contracts business  Expansion of disposable consumables busi

  14. Slide 14: Financials

    Financials Drägerwerk AGAG & Co. KGaA, 2022 © Drägerwerk & Co. KGaA, 2020 14

  15. Slide 15: Business development

    Business development Dräger Group 5y view 2017 2018 2019 2020 2021 € million € million € million € million € million Net Sales 2,572.3 2,595.0 2,780.8 3,406.3 3,328.4 % growth 1.9% 0.9% 7.2% 22.5% -2.3% % growth (fx adjusted) 3.3% 3.9% 5.9% 25.7% -1.8% Gross Profit 1,134.5 732.7 1,188.4 1,608.9 1,54

  16. Slide 16: Key figures

    Key figures Dräger Group 5y view 2017 2018 2019 2020 2021 € million € million € million € million € million Cashflow (from operating activities) 143.3 4.1 164.4 460.0 384.9 Investments 106.2 77.8 121.4 178.0 194.3 Cash and cash equivalents1 247.6 179.6 196.3 497.3 445.7 1 Net financial debt -29.2 43

  17. Slide 17: Outlook

    Outlook Drägerwerk AGAG & Co. KGaA, 2022 © Drägerwerk & Co. KGaA, 2020 17

  18. Slide 18: Outlook

    Outlook Expectations for fiscal year 2022 2021 2022 Net Sales -1.8 % -5.0 to -9.0 % (net of currency effects) 1 EBIT margin 8.2 % 1.0 to 4.0 % Dräger Value Added EUR 171.8 million EUR -70 to +25 million Drägerwerk AGAG & Co. KGaA, 2022 © Drägerwerk & Co. KGaA, 2020 18

  19. Slide 19: Drägerwerk AG & Co. KGaA, 2022

    Drägerwerk AG & Co. KGaA, 2022

  20. Slide 20: Expectation for fiscal year 2022

    Expectation for fiscal year 2022 2021 2022 Net Sales -1.8 % -5.0 to -9.0 % (net of currency effects) EBIT margin 8.2 % 1.0 to 4.0 %1 Dräger Value Added EUR 171.8 million EUR -70 to +25 million Other forecast figures: Gross profit margin 46.3 % 44.0 to 46.0 % Research and development expenses EUR 328

  21. Slide 21: The Dräger Executive Board

    The Dräger Executive Board Stefan Dräger Gert-Hartwig Lescow Rainer Klug Dr. Reiner Piske Anton Schrofner Chairman of the Deputy Chairman of the Executive Board member Executive Board member Executive Board member Executive Board Executive Board; for Safety Division for Sales & Service and for Medic

  22. Slide 22: Shareholder structure

    Shareholder structure 10,160,000 common shares (28.5 % free float) 8,600,000 preferred shares (100.0 % free float) Shareholding* Shareholding* Common shares Dr. Heinrich Dräger GmbH 3.1% 17.6% 28.5% 23.2% 68.4% 59.2% Members of the Dräger family Successors of Dr. Heinrich Dräger Dr. Heinrich Dräger

  23. Slide 23: Business development

    Business development Group / Division / Region Dräger-Group 2017 2018 2019 2020 2021 Net Sales € million € million € million € million € million Medical division 1,668.0 1,643.0 1,741.8 2,302.2 2,064.2 Safety division 904.3 952.0 1,039.1 1,104.1 1,264.2 Group 2,572.3 2,595.0 2,780.8 3,406.3 3,328.4

  24. Slide 24: Medical division

    Medical division Business development 12M - 5 year view Medical division 2017 2018 2019 2020 2021 € million € million € million € million € million Net Sales 1,668.0 1,643.0 1,741.8 2,302.2 2,064.2 Europe 842.9 833.5 868.9 1,262.6 1,069.8 Americas 358.6 343.6 370.9 443.9 428.8 Africa, Asia, Australi

  25. Slide 25: Safety division

    Safety division Business development 12M - 5 year view Safety division 2017 2018 2019 2020 2021 € million € million € million € million € million Net Sales 904.3 952.0 1,039.1 1,104.1 1,264.2 Europe 572.6 598.4 634.5 723.2 822.5 Americas 151.8 155.6 176.9 167.2 200.3 Africa, Asia, Australia 180.0 19

  26. Slide 26: Functional expenses

    Functional expenses Group 5 year view 2017 2018 2019 2020 2021 € million € million € million € million € million R&D -234.7 -252.2 -263.7 -289.6 -328.6 % of Net Sales -9.1% -9.7% -9.5% -8.5% -9.9% Sales & Marketing -566.3 -592.6 -621.9 -659.0 -672.9 % of Net Sales -22.0% -22.8% -22.4% -19.3% -20.2%

  27. Slide 27: Cash flow statement

    Cash flow statement Group 5 year view 2017 2018 2019 2020 2021 € million € million € million € million € million Group net profit 98.5 34.9 33.8 249.9 154.3 Change in inventories -30.0 -76.9 -24.5 -162.0 14.4 Change in receivables -22.4 -41.0 0.4 -95.4 122.3 Change in payables 22.2 -2.3 3.9 29.7 -15

  28. Slide 28: Balance sheet

    Balance sheet Assets 2020 2021 Change € million € million % Intangible Assets 331.0 354.1 7.0 Property, plant and equipment (incl. Right-of-use assets) 567.0 597.0 5.3 Other noncurrent assets 261.0 235.4 -9.8 Noncurrent assets 1,159.0 1,186.6 2.4 Inventories 620.8 616.8 -0.7 Trade receivables 717.2

  29. Slide 29: Balance sheet

    Balance sheet Liabilities and Equity 2020 2021 Change € million € million % Equity 1,033.8 1,260.5 21.9 Provisions for pensions and similar obligations 430.1 357.9 -16.8 Non-current personnel provisions 37.2 37.1 -0.3 Noncurrent interest bearing loans 157.8 84.8 -46.2 Non-current note loans 0.0 100.

  30. Slide 30: Simplification of the capital structure: Termination of participation certificates (1 of 2)

    Simplification of the capital structure Termination of participation certificates (1 of 2) Distributable result 32% 100% Participation certificates Common & preferred shares Series A, series K, series D 5 Securities 2 Securities 68% Common & preferred shares Drägerwerk AGAG & Co. KGaA, 2022 © Dräger

  31. Slide 31: Simplification of the capital structure: Termination of participation certificates (2 of 2)

    Simplification of the capital structure Termination of participation certificates (2 of 2) Termination of participation certificates Earnings per share In 2020, all 831,951 outstanding participation certificates were cancelled Pro forma as of December 2020, assuming full distribution and including d

  32. Slide 32: Innovation share

    Innovation share Share on new products and upgrades medical1 . New products Upgrades 40% 37% 36% 35% 30% 30% 27% 28% 25% 24% 20% 32% 20% 32% 20% 23% 25% 15% 21% 18% 10% 5% 7% 5% 5% 4% 5% 2% 3% 0% 2015 2016 2017 2018 2019 2020 2021 1 Launched in the last 3 years; products are regarded as new, if they

  33. Slide 33: Financial calendar 2022

    Financial calendar 2022 Dräger publishes preliminary results approximately 2 weeks before the dates of the quarterly reports. Preliminary results for the full year are published in January. - March 3, 2022 Final 2021 figures - Conference call - April 28, 2022 Report for the first three months 2022 C

  34. Slide 34: Contact

    Contact Drägerwerk AGAG & Co. KGaA, 2022 © Drägerwerk & Co. KGaA, 2020 34

  35. Slide 35: Thank you

    Thank you Drägerwerk AG & Co. KGaA Drägerwerk AGAG © Drägerwerk & Co. KGaA, & Co. 2022 KGaA, 2020

Drägerwerk AG & Co. KGaA — Investor Presentation (March 2022) on 6ix